Aroa Biosurgery Limited (ASX:ARX)

Market Cap	201.84M
Revenue (ttm)	76.96M
Net Income (ttm)	-3.46M
Shares Out	345.03M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	65.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,175
Average Volume	216,734
Open	0.6000
Previous Close	0.5850
Day's Range	0.5850 - 0.6000
52-Week Range	0.3500 - 0.8150
Beta	0.56
RSI	65.36
Earnings Date	Jun 30, 2025

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ARX

Financial Performance

In 2024, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2023.

Financial numbers in NZD